Drugs / GSK3536820A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03652610 | Sep 2018 → Jan 2019 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT03433482 | Aug 2018 → Jul 2019 | meningococcal meningitis | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-27 | GlaxoSmithKline | Regulatory GSK’s fully liquid Menveo meningococcal vaccine approved by European Commission gsk.com ↗
GSK plc (LSE/NYSE: GSK) today announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of Menveo (Meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine) to help protect against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W and Y. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-27 | GlaxoSmithKline | GSK’s fully liquid Menveo meningococcal vaccine approved by European Commission gsk.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3536820A | “investigational MenACWY liquid vaccine (GSK3536820A)” NCT03433482 ↗ |
| Known as | MenACWY liquid | “investigational MenACWY liquid vaccine (GSK3536820A)” NCT03433482 ↗ |
| Modality | Vaccine | “Meningococcal ACWY Conjugate Vaccine” NCT03652610 ↗ |
| Route | Intramuscular | “Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm” NCT03652610 ↗ |